Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI

The study aims is to evaluate the efficacy and tolerability of L-Carnitine on biomarkers of myocardial reperfusion injury in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI by the assessment of nitrotyrosine as an oxidative stress marker and Matrix metallopeptidase-2 (MMP-2) as a cardiac fibrosis marker

Inclusion Criteria: * Female or male aged \>18 and \< 75 years. * STEMI patients undergoing PCI. Exclusion Criteria: * Patients with a recent history of myocardial infarction (MI), a previous PCI, a previous coronary artery bypass graft, or any cardiac surgery. * A late presentation (\>12 h), unsuccessful primary PCI (residual stenosis \>50% in the culprit lesion after procedure), * Pretreatment with thrombolytic or glycoprotein IIb/IIIa inhibitor therapy before primary PCI, * Concurrent Infectious or active inflammatory disease, * Severe liver or renal disease, (aspartate aminotransferase (AST) or alanine transaminase (ALT) \> 3x ULN or Total bilirubin \> 3 x ULN), (CrCl \< 60 ml/min (based on the Cockroft-Gault equation) * Neoplasm, or hematological disorders * Pregnant or breast-feeding patients * Active participation in another clinical study * Patients taking antioxidant drugs. * History of or known allergy or intolerability to the study medications